No Change To US FDA’s Risk-Based Homeopathic Enforcement From Its OTC Monograph Overhaul
Executive Summary
Final guidance presents same descriptions of six "categories of homeopathic drug products ... potentially posing higher risks to public health” agency stated in 2019 revised draft. Agency adds reference to monograph reform in explanation of how homeopathics aren't GRASE.
You may also be interested in...
Bee Gone Children’s Nasal Swab Warning Aligns With US FDA Homeopathic Enforcement Priority
Buzzagogo’s allergy relief nasal swab found contaminated with bacillus species, leading to voluntary recall of homeopathic remedy indicated for use by children as young as 1.
Homeopathic Nasal Spray Firm Warned About Microbial Contamination Needs GMP Remediation
FDA advises additional recalls of Green Pharmaceuticals’ SnoreStop NasoSpray could be needed. Agency’s testing showed a batch of SnoreStop NasoSpray is adulterated because “it consists in whole or in part of any filthy, putrid, or decomposed substance.”
US Courts Reject Reinstating FDA's Homeopathic Drug Policy As Challenge To Change Proceeds
Decisions in US Circuit and District courts for District of Columba are on complaint by Rx drug firm MediNatura, but should resonate for OTC homeopathic firms as well as all businesses across the sector. MediNatura appealed district ruling rejecting request for injunction against FDA’s withdrawal of 1988 homeopathic CPG.